Downregulation of telomerase activity in human promyelocytic cell line using RNA interference
Tóm tắt
Telomerase is a ribonucleoprotein complex. It consists of two main components, human telomerase reverse transcriptase (hTERT) and human telomerase RNA. High telomerase activity is present in most malignant cells, but it is barely detectable in majority of somatic cells. The direct correlation between telomerase reactivation and carcinogens has made hTERT a key target for anticancer therapeutic studies. In this study, for the first time, we evaluated the ability of the new generation of short interfering RNA (siRNA) to regulate telomerase activity in the human promyelocytic leukemia cell line (HL-60). Transient transfection cell line by hTERT siRNAs resulted in statistically significant suppression of hTERT messenger RNAs which were detected by quantitative real-time polymerase chain reaction, while the expressed hTERT protein levels were measured by flow cytometry. The results of telomeric repeat amplification protocol showed that telomerase activity was significantly reduced upon transfection of the HL-60 cell line with hTERT siRNAs. The results of this study showed that telomerase activity and cell proliferation were efficiently inhibited in the hTERT siRNA-treated leukemic cell line.
Tài liệu tham khảo
Zakian VA (1995) Telomeres: beginning to understand the end. Science 270:1601–1607. doi:10.1126/science.270.5242.1601
McEachern MJ, Krauskopf A, Blackburn EH (2000) Telomeres and their control. Annu Rev Genet 34:331–358. doi:10.1146/annurev.genet.34.1.331
Oulton R, Harrington L (2000) Telomeres, telomerase, and cancer: life on the edge of genomic stability. Curr Opin Oncol 12:74–81. doi:10.1097/00001622-200001000-00013
Hoeijmakers JHJ (2001) Genome maintenance mechanisms for preventing cancer. Nature 411:366–374. doi:10.1038/35077232
Wright WE, Shay JW (1992) The two-stage mechanism controlling cellular senescence and immortalization. Exp Gerontol 27:383–389. doi:10.1016/0531-5565(92)90069-C
Blackburn EH (1992) Telomerases. Annu Rev Biochem 61:113–129. doi:10.1146/annurev.bi.61.070192.000553
Greider CW (1996) Telomere length regulation. Annu Rev Biochem 65:337–365. doi:10.1146/annurev.bi.65.070196.002005
Weinrich SL, Pruzan R, Ma L, Ouellette M, Tesmer VM, Holt SE et al (1997) Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT. Nat Genet 17:498–502. doi:10.1038/ng1297-498
Nakayama JI, Tahara H, Tahara E, Saito M, Ito K, Nakamura H et al (1998) Telomerase activation by HTRT in human normal fibroblasts and hepatocellular carcinomas. Nat Genet 18:65–68. doi:10.1038/ng0198-65
Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al (1998) Extension of life-span by introduction of telomerase into normal human cells. Science 279:349–352. doi:10.1126/science.279.5349.349
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PLC et al (1994) Specific association of human telomerase activity with immortal cells and cancer. Science 266:2011–2015. doi:10.1126/science.7605428
Jiang XR, Jimenez G, Chang E, Frolkis M, Kusler B, Sage M et al (1999) Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21:111–114. doi:10.1038/5056
Zhang TC, Schmitt MT, Mumford JL (2003) Effects of arsenic on telomerase and telomeres in relation to cell proliferation and apoptosis in human keratinocytes and leukemia cells in vitro. Carcinogenesis 24:1811–1817. doi:10.1093/carcin/bgg141
Liu L, Berletch JB, Green JG, Pate MS, Andrews LG, Tollefsbol TO (2004) Telomerase inhibition by retinoids precedes cytodifferentiation of leukemia cells and may contribute to terminal differentiation. Mol Cancer Ther 3:1003–1009
Liu J-J, Wu X-Y, Peng J, Pan X-L, Lu H-L (2004) Antiproliferation effects of oridonin on HL-60 cells. Ann Hematol 83:691–695. doi:10.1007/s00277-004-0919-y
Yamaguchi T, Takahashi H, Harada Y, Yoshikawa M, Iyono S, Inomata M et al (2004) Telomere shortening in human HL60 cells by treatment with deoxyguanosine analogs. Nucleic Acids Symp Ser 48:187–188. doi:10.1093/nass/48.1.187
Pizzimenti S, Briatore F, Laurora S, Toaldo C, Maggio M, De Grandi M et al (2006) 4-Hydroxynonenal inhibits telomerase activity and hTERT expression in human leukemic cell lines. Free Radic Biol Med 40:1578–1591. doi:10.1016/j.freeradbiomed.2005.12.024
Wang F, Sun L, Sun H, Fan Q, Le X, Zhang Q (2007) Inhibition hTERT antisense oligodeoxynucleotide changes proliferation and telomerase activity of HL-60 cell. Life Sci J 4:17–21
Hannon GJ (2002) RNA interference. Nature 418:244–251. doi:10.1038/418244a
Hammond SM, Caudy AA, Hannon GJ (2001) Post-transcriptional gene silencing by double-stranded RNA. Nat Rev Genet 2:110–119. doi:10.1038/35052556
Zhang PH, Zou L, Tu ZG (2006) RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity. J Surg Res 131:143–149. doi:10.1016/j.jss.2005.09.017
Gandellini P, Folini M, Bandiera R, De Cesare M, Binda M, Veronese S et al (2007) Down-regulation of human telomerase reverse transcriptase through specific activation of RNAi pathway quickly results in cancer cell growth impairment. Biochem Pharmacol 73:1703–1714. doi:10.1016/j.bcp. 2007.01.035
De Souza Nascimento P, Alves G, Fiedler W (2006) Telomerase inhibition by an siRNA directed against hTERT leads to telomere attrition in HT29 cells. Oncol Rep 16:423–428
Zheng JN, Sun YF, Pei DS, Liu JJ, Chen JC, Li W, Sun XQ, Shi QD, Han RF, Ma TX (2006) Inhibition of proliferation and induction of apoptosis in human renal carcinoma cells by anti-telomerase small interfering RNAs. Acta Biochim Biophys Sin (Shanghai) 38:500–506. doi:10.1111/j.1745-7270.2006.00182.x
Shammas MA, Koley H, Batchu RB, Bertheau RC, Protopopov A, Munshi NC, Goyal RK (2005) Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential. Mol Cancer 4:24. doi:10.1186/1476-4598-4-24
Ning S, Fuessel S, Kotzsch M, Kraemer K, Kappler M, Schmidt U et al (2004) siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth. Int J Oncol 25:1065–1071
Tebes SJ, Johnson NC, Fiorica JV, Kruk PA (2005) Inhibition of telomerase in ovarian cancer using siRNA technology. J Clin Oncol 23:3182 Meeting abstracts
Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A (2004) Rational siRNA design for RNA interference. Nat Biotechnol 22:326–330. doi:10.1038/nbt936
Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162:156–159. doi:10.1016/0003-2697(87)90021-2
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 25:402–408
Lin Y, Miyamoto N, Fujinami K, Uemura H, Hosaka M, Iwasaki Y, Kubota Y (1996) Telomerase activity in human bladder cancer. Clin Cancer Res 2:929–932
Ohyashki J, Sashida G, Tauchi T, Ohyashiki K (2002) Telomeres and telomerase in hematologic neoplasia. Oncogene 21:680–687. doi:10.1038/sj.onc.1205075
Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M, Ariga H, Inoue M (2000) Sp-1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28:669–677. doi:10.1093/nar/28.3.669
Yamada O, Ozaki K, Nakatake M, Akiyama M, Kawauchi K, Matsuoka R (2008) Multistep regulation of telomerase during differentiation of HL-60 cells. J Leukoc Biol 83:1–9
Guittat L, Alberti P, Gomez D, De Cian A, Pennarun G, Lemarteleur T et al (2004) Targeting human telomerase for cancer therapeutics. Cytotechnology 45:75–90. doi:10.1007/s10616-004-5127-z
Saretzki G (2003) Telomerase inhibition as cancer therapy. Cancer Lett 194:209. doi:10.1016/S0304-3835(02)00708-5
Wang Q, Liu M, Kozasa T, Rothestein JD, Sternweis PC, Neubig RR (2004) Ribozyme and siRNA-mediated suppression of RGS-containing RhoGEF proteins. Methods Enzymol 389:244–265. doi:10.1016/S0076-6879(04)89015-3
Lu PY, Xie FY, Woodle MC (2003) siRNA-mediated antitumorigenesis for drug target validation and therapeutics. Curr Opin Mol Ther 5:225–234
Kosciolek BA, Kalantidis K, Tabler M, Rowley PT (2003) Inhibition of telomerase activity in human cancer cells by RNA interference. Mol Cancer Ther 2:209–216
Hu B, Insel RA (1999) Up-regulation of telomerase in human B lymphocytes occurs independently of cellular proliferation and with expression of telomerase catalytic subunit. Eur J Immunol 29:3745–3753. doi:10.1002/(SICI)1521-4141(199911)29:11<3745::AID-IMMU3745>3.0.CO;2-1
Nowak T, Januszkiewicz D, Zawada M, Pernak M, Lewandowski K, Rembowska J et al (2006) Amplification of hTERT and hTERC genes in leukemic cells with high expression and activity of telomerase. Oncol Rep 16:301–305
Casillas MA Jr, Brotherton SL, Andrews LG, Ruppert JM, Tollefsbol TO (2003) Induction of endogenous telomerase (hTERT) by c-Myc in WI-38 fibroblasts transformed with specific genetic elements. Gene 316:57–65. doi:10.1016/S0378-1119(03)00739-X
Zou L, Zhang P, Luo C, Tu Z (2006) shRNA-targeted hTERT suppress cell proliferation of bladder cancer by inhibiting telomerase activity. Cancer Chemother Pharmacol 57:328–334. doi:10.1007/s00280-005-0056-x
Zou L, Zhang PH, Luo CL, Tu ZG (2005) Transcript regulation of human telomerase reverse transcriptase by c-myc and mad1. Acta Biochim Biophys Sin (Shanghai) 37:32–38
Lai SR, Cunningham AP, Huynh VQ, Andrews LG, Tollefsbol TO (2007) Evidence of extra-telomeric effects of hTERT and its regulation involving a feedback loop. Exp Cell Res 313:322–330. doi:10.1016/j.yexcr.2006.10.014
Huh HJ, Huh JW, Yoo ES, Seong CM, Lee M, Hong KS, Chung WS (2005) hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia. Am J Hematol 79:267–273. doi:10.1002/ajh.20394